Advertisement
Invex Therapeutics Ltd

Invex Therapeutics Ltd (IXC.AX) Stock Competitors & Peer Comparison

See (IXC.AX) competitors and their performances in Stock Market.

IXC.AXASX
HealthcareBiotechnology
$0.10
$0.00(0.00%)
Australian Market opens in 50h 7m
Advertisement

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
IXC.AXA$0.10+0.00%7.1M-8.57-A$0.01N/A
CSL.AXA$121.81+3.45%58.3B13.10A$9.30+3.62%
TLX.AXA$16.88-1.75%5.7B-609.17-A$0.03N/A
MSB.AXA$2.06+0.49%2.7B-13.85-A$0.15N/A
NEU.AXA$16.74-1.53%2.1B71.26A$0.23N/A
PYC.AXA$1.54-4.64%895M-33.66-A$0.05N/A
OPT.AXA$0.60+0.00%820.8M6.14A$0.10N/A
CUV.AXA$10.25-0.10%516.7M15.91A$0.64+0.49%
RAC.AXA$2.29+0.44%449M-110.63-A$0.02N/A
SPL.AXA$0.74+3.52%309.4M116.67A$0.01N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

IXC.AX vs CSL.AX Comparison July 2026

IXC.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, IXC.AX stands at 7.1M. In comparison, CSL.AX has a market cap of 58.3B. Regarding current trading prices, IXC.AX is priced at A$0.10, while CSL.AX trades at A$121.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

IXC.AX currently has a P/E ratio of -8.57, whereas CSL.AX's P/E ratio is 13.10. In terms of profitability, IXC.AX's ROE is -0.17%, compared to CSL.AX's ROE of +0.08%. Regarding short-term risk, IXC.AX is less volatile compared to CSL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for IXC.AX.Check CSL.AX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions